{"id":496961,"date":"2026-06-13T01:03:10","date_gmt":"2026-06-13T01:03:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/496961\/"},"modified":"2026-06-13T01:03:10","modified_gmt":"2026-06-13T01:03:10","slug":"early-anticoagulation-may-improve-outcomes-without-increasing-bleeding-in-acute-leukemia-associated","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/496961\/","title":{"rendered":"Early Anticoagulation May Improve Outcomes Without Increasing Bleeding in Acute Leukemia\u2013Associated"},"content":{"rendered":"<p>Severe thrombocytopenia and NSTEMI in patients with acute leukemia have always been a clinical issue with limited information on how to manage the disease properly. This patient subgroup is often excluded from clinical trials. Now, a retrospective study from West Virginia University points to something the field has mostly been too nervous to try: giving these patients unfractionated heparin early, within the first day. Survival looked better, and the bleeding everyone braces for didn\u2019t show up.<\/p>\n<p>The work was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and recognized with a Conquer Cancer Merit Award. Led by Shanawar Ali Waris, MD, the group went into the TriNetX network, which pools records from more than 147 million patients, and pulled adults with acute leukemia who had a first NSTEMI after their cancer diagnosis and a platelet count under 50,000 within 24 hours of the event. Anyone with a prior intracranial bleed or on chronic anticoagulation was excluded.<\/p>\n<p>After 1:1 propensity matching on demographics and cardiac risk factors, they had 517 patients in each arm: heparin within 24 hours versus no parenteral anticoagulation. Median age was 67. Two-thirds were men, and three-quarters were White. Older, sick, comorbid.<\/p>\n<p>The survival signal was not subtle. At 30 days, early heparin carried an HR for death of 0.72 (95% CI, 0.58-0.89). At 90 days, the HR was 0.73 (95% CI, 0.60-0.87), and at 1 year, it was 0.80 (95% CI, 0.69-0.94). Put another way, that\u2019s a 28% lower risk of death at a month, settling to about a fifth lower out at a year. The Kaplan-Meier curves split early and never crossed back.<\/p>\n<p>Then the part people will go straight to, bleeding. Major bleeding, a composite of intracranial and GI hemorrhage, came in at 13.6% with heparin and 12.8% without at 7 days. At 30 days, it was 17% versus 16.1%. That\u2019s a point or so of absolute difference among patients with platelet counts under 50,000.<\/p>\n<p>Why does any of this matter? Because the guidelines genuinely don\u2019t cover it. The 2025 ACC\/AHA acute coronary syndrome guideline is thorough, but it\u2019s built around type 1 MI and says nothing specific about anticoagulating someone with active leukemia and severe thrombocytopenia. That silence isn\u2019t really an oversight; it\u2019s a consequence. Cancer patients have been excluded from cardiovascular randomized trials for years, which is exactly why anyone facing this scenario has been working off expert opinion.<\/p>\n<p>Keep the skepticism dialed up, though. This is observational. Propensity scores balance what you measured, not what you didn\u2019t, and the obvious worry is that the sickest patients, the ones already dying, were the ones who never got offered heparin. Confounding by indication like that can manufacture a survival benefit out of nothing. The bleeding end point is also a bit ambitious, combining two pretty different events into one rate.<\/p>\n<p>A couple of questions the data leaves open. Does the survival edge hold up against a tougher comparison, heparin versus a more aggressive antithrombotic or an early invasive approach, instead of doing nothing? And is there a platelet count low enough that the math finally tips the other way? Twenty thousand? Ten?<\/p>\n<p>None of that gets settled here. What the study does is put a number where there wasn\u2019t one. For treatment of severe thrombocytopenia and NSTEMI in patients with acute leukemia, early heparin treatment was associated with living longer and did not increase bleeding. It won\u2019t end the argument. But it gives the people having that argument something to point to.<\/p>\n","protected":false},"excerpt":{"rendered":"Severe thrombocytopenia and NSTEMI in patients with acute leukemia have always been a clinical issue with limited information&hellip;\n","protected":false},"author":2,"featured_media":496962,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-496961","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/496961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=496961"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/496961\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/496962"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=496961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=496961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=496961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}